Atypical hemolytic uremic syndrome: Treatment of atypical hemolytic uremic syndrome to inhibit complement-mediated thrombotic microangiopathy.
Generalized myasthenia gravis, refractory: Treatment of refractory generalized myasthenia gravis in adults who are antiacetylcholine receptor antibody positive.
Neuromyelitis optica spectrum disorder: Treatment of neuromyelitis optica spectrum disorder in adults who are aquaporin-4-antibody positive.
Paroxysmal nocturnal hemoglobinuria: Treatment of paroxysmal nocturnal hemoglobinuria to reduce hemolysis

Monoclonal Antibody; Monoclonal Antibody, Complement Inhibitor

Onset of action: PNH: Reduced hemolysis: ?1 week
Distribution: 5 to 8 L
Half-life elimination: ~270 to 414 hours (during plasma exchange the half-life is reduced to 1.26 hours)

Unresolved serious Neisseria meningitidis infection; patients not currently vaccinated against Neisseria meningitidis

Available data, although limited, do not suggest safety concerns when eculizumab is used during pregnancy.

Eculizumab may be present in breast milk. According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother.

Cardiovascular: Hypertension , tachycardia, peripheral edema, hypotension

Central nervous system: Headache, insomnia, fatigue, dizziness

Dermatologic: Skin rash, pruritus)
Endocrine & metabolic: Hypokalemia

Gastrointestinal: Diarrhea, vomiting, nausea, abdominal pain, gastroenteritis

Genitourinary: Urinary tract infection, urinary tract symptoms, proteinuria

Hematologic & oncologic: Anemia, neoplasm, leukopenia

Infection: Infection, influenza

Local: Catheter infection

Neuromuscular & skeletal: Asthenia, back pain, arthralgia, musculoskeletal pain, muscle spasm

Ophthalmic: Eye disease

Renal: Renal insufficiency

Respiratory: Cough, nasopharyngitis, nasal congestion, upper respiratory tract infection, rhinitis, bronchitis

Miscellaneous: Fever

Atypical hemolytic uremic syndrome: IV: Induction: 900 mg weekly for 4 doses; Maintenance: 1,200 mg at week 5, then 1,200 mg every 2 weeks thereafter.
Generalized myasthenia gravis, refractory: IV: Induction: 900 mg weekly for 4 doses; Maintenance: 1,200 mg at week 5, then 1,200 mg every 2 weeks thereafter.
Neuromyelitis optica spectrum disorder: IV: Induction: 900 mg weekly for 4 doses; Maintenance: 1,200 mg at week 5, then 1,200 mg every 2 weeks thereafter.
Paroxysmal nocturnal hemoglobinuria: IV: Induction: 600 mg weekly for 4 doses; Maintenance: 900 mg at week 5; then 900 mg every 2 weeks thereafter.

Atypical hemolytic uremic syndrome (aHUS): Infants, Children, and Adolescents:
Patient weight:
5 kg to <10 kg: IV: Induction: 300 mg weekly for 1 dose; Maintenance: 300 mg at week 2, then 300 mg every 3 weeks.
10 kg to <20 kg: IV: Induction: 600 mg weekly for 1 dose; Maintenance: 300 mg at week 2, then 300 mg every 2 weeks.
20 kg to <30 kg: IV: Induction: 600 mg weekly for 2 doses; Maintenance: 600 mg at week 3, then 600 mg every 2 weeks.
30 kg to <40 kg: IV: Induction: 600 mg weekly for 2 doses; Maintenance: 900 mg at week 3, then 900 mg every 2 weeks.
?40 kg: Induction: IV: 900 mg weekly for 4 doses; Maintenance: 1,200 mg at week 5, then 1,200 mg every 2 weeks.

There are no dosage adjustments provided in the manufacturer's labeling

There are no dosage adjustments provided in the manufacturer's labeling